「in vitroinvivo」の検索結果
165件：91～95件目を表示
-
CEO Message | About Senju | SENJU Pharmaceutical
Since Senju was established in 1947, we have been making efforts for more than 70 years to develop excellent medicines and services focusing on the ophthalmology field through our unique ideas and R&a...
https://www.senju.co.jp/english/about/message.html -
ysis Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of software for dry-eye analysis in Jap...
https://www.senju.co.jp/system/files/content_news/2024-09/ENG_20240906.pdf -
CEO Message | About Senju | SENJU Pharmaceutical
Since Senju was established in 1947, we have been making efforts for more than 70 years to develop excellent medicines and services focusing on the ophthalmology field through our unique ideas and R&a...
http://www.senju.co.jp/english/about/message.html -
March 7, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Announcement of Licensing Agreement with Brill International Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr...
https://www.senju.co.jp/system/files/content_news/2025-03/ENG_20250307.pdf -
アバレプト懸濁性点眼液0.3%
、目の症状、日常生活への 影響に関する15項目の質問で構成される。総合的なQOL障害 度は合計スコアで評価され、スコアが高いほど状態が悪いこ とを示す。 O O N H OH H F F F R E in vitro in vitro N H in vitro 21. 承認条件 医薬品リスク管理計画を策定の上、適切に実施すること。 22. 包装 プラスチック点眼容器 5mL×10、5mL×50 2...
https://www.senju.co.jp/system/files/product_other_file/2026-03/avarept_202512_C3.pdf